300 related articles for article (PubMed ID: 20625302)
1. Distortion-product otoacoustic emission test performance for ototoxicity monitoring.
Reavis KM; McMillan G; Austin D; Gallun F; Fausti SA; Gordon JS; Helt WJ; Konrad-Martin D
Ear Hear; 2011 Feb; 32(1):61-74. PubMed ID: 20625302
[TBL] [Abstract][Full Text] [Related]
2. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
[TBL] [Abstract][Full Text] [Related]
3. ABR obtained from time-efficient train stimuli for cisplatin ototoxicity monitoring.
Dille MF; Ellingson RM; McMillan GP; Konrad-Martin D
J Am Acad Audiol; 2013 Oct; 24(9):769-81. PubMed ID: 24224985
[TBL] [Abstract][Full Text] [Related]
4. Ototoxicity risk assessment combining distortion product otoacoustic emissions with a cisplatin dose model.
Dille MF; McMillan GP; Reavis KM; Jacobs P; Fausti SA; Konrad-Martin D
J Acoust Soc Am; 2010 Sep; 128(3):1163-74. PubMed ID: 20815453
[TBL] [Abstract][Full Text] [Related]
5. [Otoacoustic emissions measurements in children during the chemotherapy because of the acute lymphoblastic leukemia].
Lisowska G; Namysłowski G; Hajduk A; Polok A; Tomaszewska R; Misiołek M
Otolaryngol Pol; 2006; 60(3):415-20. PubMed ID: 16989457
[TBL] [Abstract][Full Text] [Related]
6. Accuracy of distortion-product otoacoustic emissions-based ototoxicity monitoring using various primary frequency step-sizes.
McMillan GP; Konrad-Martin D; Dille MF
Int J Audiol; 2012 Sep; 51(9):689-96. PubMed ID: 22676700
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of a cisplatin dose-ototoxicity model.
Dille MF; Wilmington D; McMillan GP; Helt W; Fausti SA; Konrad-Martin D
J Am Acad Audiol; 2012; 23(7):510-21. PubMed ID: 22992258
[TBL] [Abstract][Full Text] [Related]
8. Test-retest reliability of distortion-product thresholds compared to behavioral auditory thresholds.
Bader K; Dierkes L; Braun LH; Gummer AW; Dalhoff E; Zelle D
Hear Res; 2021 Jul; 406():108232. PubMed ID: 33984603
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of audiometric threshold shift criteria for ototoxicity monitoring.
Konrad-Martin D; James KE; Gordon JS; Reavis KM; Phillips DS; Bratt GW; Fausti SA
J Am Acad Audiol; 2010 May; 21(5):301-14; quiz 357. PubMed ID: 20569665
[TBL] [Abstract][Full Text] [Related]
10. Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children.
Stavroulaki P; Apostolopoulos N; Segas J; Tsakanikos M; Adamopoulos G
Int J Pediatr Otorhinolaryngol; 2001 May; 59(1):47-57. PubMed ID: 11376818
[TBL] [Abstract][Full Text] [Related]
11. Distortion product otoacoustic emission test performance for a priori criteria and for multifrequency audiometric standards.
Gorga MP; Neely ST; Dorn PA
Ear Hear; 1999 Aug; 20(4):345-62. PubMed ID: 10466570
[TBL] [Abstract][Full Text] [Related]
12. [Effect of inner ear hearing loss on delayed otoacoustic emissions (TEOAE) and distortion products (DPOAE)].
Hoth S
Laryngorhinootologie; 1996 Dec; 75(12):709-18. PubMed ID: 9081275
[TBL] [Abstract][Full Text] [Related]
13. Distortion-product otoacoustic emissions: a useful test for monitoring ototoxicity induced by pegylated interferon and ribavirin treatment in patients with chronic hepatitis C.
Casale M; Mazzarelli C; Vespasiani Gentilucci U; Potena M; Pappacena M; Faiella F; Galati G; Salvinelli F; Picardi A
Int J Immunopathol Pharmacol; 2012; 25(2):551-6. PubMed ID: 22697091
[TBL] [Abstract][Full Text] [Related]
14. Clinical test performance of distortion-product otoacoustic emissions using new stimulus conditions.
Johnson TA; Neely ST; Kopun JG; Dierking DM; Tan H; Gorga MP
Ear Hear; 2010 Feb; 31(1):74-83. PubMed ID: 19701088
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Variability of Distortion-Product Otoacoustic Emissions in Infants and Children and Its Relation to Pediatric Ototoxicity Monitoring.
Konrad-Martin D; Knight K; McMillan GP; Dreisbach LE; Nelson E; Dille M
Ear Hear; 2020; 41(2):239-253. PubMed ID: 29280917
[TBL] [Abstract][Full Text] [Related]
16. From laboratory to clinic: a large scale study of distortion product otoacoustic emissions in ears with normal hearing and ears with hearing loss.
Gorga MP; Neely ST; Ohlrich B; Hoover B; Redner J; Peters J
Ear Hear; 1997 Dec; 18(6):440-55. PubMed ID: 9416447
[TBL] [Abstract][Full Text] [Related]
17. Pure-tone threshold estimation from extrapolated distortion product otoacoustic emission I/O-functions in normal and cochlear hearing loss ears.
Boege P; Janssen T
J Acoust Soc Am; 2002 Apr; 111(4):1810-8. PubMed ID: 12002865
[TBL] [Abstract][Full Text] [Related]
18. Identification of neonatal hearing impairment: evaluation of transient evoked otoacoustic emission, distortion product otoacoustic emission, and auditory brain stem response test performance.
Norton SJ; Gorga MP; Widen JE; Folsom RC; Sininger Y; Cone-Wesson B; Vohr BR; Mascher K; Fletcher K
Ear Hear; 2000 Oct; 21(5):508-28. PubMed ID: 11059707
[TBL] [Abstract][Full Text] [Related]
19. Effect of calibration method on distortion-product otoacoustic emission measurements at and around 4 kHz.
Reuven ML; Neely ST; Kopun JG; Rasetshwane DM; Allen JB; Tan H; Gorga MP
Ear Hear; 2013; 34(6):779-88. PubMed ID: 24165303
[TBL] [Abstract][Full Text] [Related]
20. Cochlear Mechanisms and Otoacoustic Emission Test Performance.
Go NA; Stamper GC; Johnson TA
Ear Hear; 2019; 40(2):401-417. PubMed ID: 29952805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
